Physician profile
Mary Deherrera Codo
NPI 1568504439
$6,001.54
in general payments reported to CMS, 2019-2025
30 companies · $1,559 in 2025
The $1,559 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $484 · 2021: $713 · 2022: $674 · 2023: $851 · 2024: $1,170 · 2025: $1,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,580.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,865.17 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $996.45 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $442.95 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $439.85 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $265.28 | 2020-2025 | Farxiga |
| Amgen INC. | $263.31 | 2019-2025 | Tepezza, Evenity, Prolia |
| Dexcom, INC. | $230.10 | 2019-2024 | Dexcom G6 Transmitter |
| Insulet Corporation | $195.71 | 2023-2025 | Omnipod |
| Amneal Pharmaceuticals LLC | $127.23 | 2019-2025 | Unithroid |
| Tandem Diabetes Care, INC. | $125.24 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Janssen Pharmaceuticals, INC | $109.13 | 2019 | |
| Abbvie INC. | $103.76 | 2020-2025 | Synthroid |
| Radius Health, INC. | $101.12 | 2025 | Tymlos |
| Sequel Med Tech, LLC | $88.50 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.22 | 2024-2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $85.57 | 2025 | Yorvipath |
| Antares Pharma, INC. | $73.16 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Beta Bionics, INC. | $60.69 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amphastar Pharmaceuticals, INC. | $58.73 | 2024-2025 | |
| Almatica Pharma LLC | $57.86 | 2024-2025 | Teriparatide |
| Xeris Pharmaceuticals, INC. | $40.30 | 2020-2024 | Gvoke Hypopen |
| Medtronic, INC. | $38.34 | 2023-2025 | Minimed 780g |
| Ibsa Pharma INC. | $32.54 | 2025 | Licart, Flector, Tirosint |
| Chiesi USA, INC. | $23.81 | 2025 | Mycapssa |
| Mannkind Corporation | $17.89 | 2025 | |
| Amryt Pharma Holdings Ltd | $16.72 | 2022 | |
| Theracosbio, LLC | $16.33 | 2024 | Brenzavvy |
| Corcept Therapeutics | $15.95 | 2025 | Korlym |
| Medtronic Minimed, INC. | $11.75 | 2019 | |
| Shire North American Group INC | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Codo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.